An annual output of 500,000 Human Papilloma Virus vaccinedesign workshopAbstractOne of the most common female malignancy is cervical cancer,the cancer is insecond place in the female reproductive system,and is also the world's fourth mostcommon fatal cancer,studies confirm that more than 95%of cervical cancersassociated with human Papilloma Virus HPV)infection.Prophylactic HPVvaccination as an important means of preventing cervical cancer.HPV vaccine research and development of domestic enterprises includingShanghai Institute of Biological Products Co.,Ltd,National Vaccine SerumInstitute,BravoVax,Shanghai Zerun Biotechnology Co.,Ltd,INNOVAX.Which bythe INNOVAX.In Manhattan bivalent human Papilloma Virus vaccine (trade name:Cecolin)on 31 December 2019 by the State Food and Drug Administration approvedfor marketing registration applications,2020 January 3 pm,Manhattan has begunformal production of vaccines,the vaccine is a recombinant human China's firstindependently developed HPV vaccines,HPV vaccine by the break Merck and GlaxoSmith Kline (GSK)production monopoly.But a company's production is hardlyenough to supply the whole of China.Therefore,this design will cancer vaccinerecombinant Escherichia coli as the raw material,the application of high-densityfermentation process,after the production of the protein purification techniques,mixed with other ingredients Cecolin same.This designed to produce 500,000 HPV vaccine production plant,eachcomprising the recombinant protein 40ugHPV16,20ugHPV18 recombinant protein,210ug aluminum salt,Al (OH)3,packaged as a pre-filled syringe,an injection dosageform,specifications for 60ug /0.5mL/support.This design combines the cervicalcancer vaccine production of the actual situation,access to a large number ofdocuments and standards,completed the process of design and plant layout design,materials were calculated heat balance,selection fermenter design,major equipment.Keywords:Human Papilloma;high-density fermentation process;geneticallyengineered vaccine;Design Workshop
暂无评论内容